BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
250.30
-3.09 (-1.22%)
At close: Jul 11, 2025, 4:00 PM
250.30
0.00 (0.00%)
After-hours: Jul 11, 2025, 4:41 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Collaboration | 30.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Collaboration Growth | -85.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Product | 3.78B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Product Growth | 63.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
REVLIMID | 36.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
REVLIMID Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIDAZA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIDAZA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ABRAXANE | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ABRAXANE Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRUKINSA | 2.64B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRUKINSA Growth | 88.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Tislelizumab | 620.84M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Tislelizumab Growth | 14.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
XGEVA | 224.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
XGEVA Growth | 116.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product | 60.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BLINCYTO | 74.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BLINCYTO Growth | 45.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
POBEVCY | 53.51M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
POBEVCY Growth | -13.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pamiparib | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KYPROLIS | 66.17M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KYPROLIS Growth | 46.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
U.S. | 1.96B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
U.S. Growth | 65.24% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Growth | 26.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 362.63M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | 73.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World | 78.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Growth | 161.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|